Loading...
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and the high serum concentration of C5 pose challenges to drug development that...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082616/ https://ncbi.nlm.nih.gov/pubmed/31978221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003399 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|